Alkahest is a clinical stage biopharmaceutical company that specializes in developing transformative therapies for neurodegenerative and age-related diseases. They have a deep understanding of the plasma proteome in aging and disease, which allows them to create groundbreaking therapies. Their unique approach involves harnessing chronokines, the proteins that increase or decrease with age, to create therapeutics that modulate a wide range of deleterious age-related disease mechanisms with precision.

Their target diseases include Alzheimer's disease, Parkinson's disease, Age-related Macular Degeneration (AMD), and others. Alkahest is developing clinical candidates that either increase or decrease the levels of key circulating chronokines. This helps to promote innate and natural restorative biological processes or inhibit pathological degenerative processes.

Their therapeutics include traditional pharmaceutical modalities, highly selected and refined plasma fractions, and other methods for antagonizing or supplementing the most biologically active chronokines. The company has a strong pipeline of products in various stages of development, targeting diseases like Wet AMD, Parkinson's disease, Alzheimer's disease, and more. Alkahest has a dedicated and experienced team focused on making a difference and improving the lives of patients with these critical diseases